C-E-Cad maintains the tumorigenicity of glioma stem cells by binding to the EGFR CR2 domain via a unique 14-amino-cid carboxy terminus, which activates EGFR independently of EGF (Gao et al., 2021). Here, EGFR is linked to central nervous system cancer.